Literature DB >> 34735627

The histopathologist is essential in molecular pathology quality assurance for solid tumours.

Marc Lucas Ooft1,2, Jeanne Boissiere3, Stefano Sioletic3,4.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 34735627     DOI： 10.1007/s00428-021-03226-y

Source DB:  PubMed          Journal:  Virchows Arch        ISSN： 0945-6317            Impact factor:   4.064


× No keyword cloud information.
  11 in total

Review 1.  Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists.

Authors:  Lawrence J Jennings; Maria E Arcila; Christopher Corless; Suzanne Kamel-Reid; Ira M Lubin; John Pfeifer; Robyn L Temple-Smolkin; Karl V Voelkerding; Marina N Nikiforova
Journal:  J Mol Diagn       Date:  2017-03-21       Impact factor: 5.568

2.  The estimation of tumor cell percentage for molecular testing by pathologists is not accurate.

Authors:  Alexander J J Smits; J Alain Kummer; Peter C de Bruin; Mijke Bol; Jan G van den Tweel; Kees A Seldenrijk; Stefan M Willems; G Johan A Offerhaus; Roel A de Weger; Paul J van Diest; Aryan Vink
Journal:  Mod Pathol       Date:  2013-07-26       Impact factor: 7.842

3.  EGFR and KRAS quality assurance schemes in pathology: generating normative data for molecular predictive marker analysis in targeted therapy.

Authors:  Erik Thunnissen; Judith V M G Bovée; Hans Bruinsma; Adriaan J C van den Brule; Winand Dinjens; Daniëlle A M Heideman; Els Meulemans; Petra Nederlof; Carel van Noesel; Clemens F M Prinsen; Karen Scheidel; Peter M van de Ven; Roel de Weger; Ed Schuuring; Marjolijn Ligtenberg
Journal:  J Clin Pathol       Date:  2011-10       Impact factor: 3.411

4.  Adequately defining tumor cell proportion in tissue samples for molecular testing improves interobserver reproducibility of its assessment.

Authors:  Benoît Lhermitte; Caroline Egele; Noëlle Weingertner; Damien Ambrosetti; Bérengère Dadone; Valérie Kubiniek; Fanny Burel-Vandenbos; John Coyne; Jean-François Michiels; Marie-Pierre Chenard; Etienne Rouleau; Jean-Christophe Sabourin; Jean-Pierre Bellocq
Journal:  Virchows Arch       Date:  2016-11-16       Impact factor: 4.064

Review 5.  Tumor Heterogeneity in Breast Cancer.

Authors:  Gulisa Turashvili; Edi Brogi
Journal:  Front Med (Lausanne)       Date:  2017-12-08

Review 6.  Guidance for laboratories performing molecular pathology for cancer patients.

Authors:  Ian A Cree; Zandra Deans; Marjolijn J L Ligtenberg; Nicola Normanno; Anders Edsjö; Etienne Rouleau; Francesc Solé; Erik Thunnissen; Wim Timens; Ed Schuuring; Elisabeth Dequeker; Samuel Murray; Manfred Dietel; Patricia Groenen; J Han Van Krieken
Journal:  J Clin Pathol       Date:  2014-07-10       Impact factor: 3.411

Review 7.  Integration of next-generation sequencing in clinical diagnostic molecular pathology laboratories for analysis of solid tumours; an expert opinion on behalf of IQN Path ASBL.

Authors:  Zandra C Deans; Jose Luis Costa; Ian Cree; Els Dequeker; Anders Edsjö; Shirley Henderson; Michael Hummel; Marjolijn Jl Ligtenberg; Marco Loddo; Jose Carlos Machado; Antonio Marchetti; Katherine Marquis; Joanne Mason; Nicola Normanno; Etienne Rouleau; Ed Schuuring; Keeda-Marie Snelson; Erik Thunnissen; Bastiaan Tops; Gareth Williams; Han van Krieken; Jacqueline A Hall
Journal:  Virchows Arch       Date:  2016-09-27       Impact factor: 4.064

8.  Neoplastic cell percentage estimation in tissue samples for molecular oncology: recommendations from a modified Delphi study.

Authors:  Kelly Dufraing; J Henricus van Krieken; Gert De Hertogh; Gerald Hoefler; Anca Oniscu; Tine P Kuhlmann; Wilko Weichert; Caterina Marchiò; Ari Ristimäki; Aleš Ryška; Jean-Yves Scoazec; Elisabeth Dequeker
Journal:  Histopathology       Date:  2019-07-18       Impact factor: 5.087
View more
  1 in total

Review 1.  Daily Practice Assessment of KRAS Status in NSCLC Patients: A New Challenge for the Thoracic Pathologist Is Right around the Corner.

Authors:  Christophe Bontoux; Véronique Hofman; Patrick Brest; Marius Ilié; Baharia Mograbi; Paul Hofman
Journal:  Cancers (Basel)       Date:  2022-03-23       Impact factor: 6.639
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.